In this retrospective study, we investigated the potential application of serum stem cell growth factor beta (SCGF-β) as a biomarker for predicting the therapeutic response and prognosis in patients with hepatocellular carcinoma (HCC) undergoing atezolizumab and bevacizumab (Atz/Bev) combination therapy. Pre- and post-treatment serum SCGF-β levels were measured and analyzed in relation to treatment outcomes and overall survival (OS). Pretreatment SCGF-β levels were associated with treatment response. Patients with SCGF-β levels exceeding the 163,295 pg/mL cutoff experienced significantly reduced OS, with a median OS of 12.03 months, compared to 28.87 months in those with SCGF-β levels at or below this threshold. These findings suggest that SCGF-β can serve as a predictive marker for clinical outcomes in HCC treatment, highlighting the need for prospective studies to further validate these results and clarify the mechanisms underlying SCGF-β-related therapeutic resistance.
在本回顾性研究中，我们探讨了血清干细胞生长因子β（SCGF-β）作为生物标志物在预测接受阿特珠单抗联合贝伐珠单抗（Atz/Bev）治疗的肝细胞癌（HCC）患者治疗反应及预后的潜在应用价值。通过检测并分析治疗前后血清SCGF-β水平与治疗结果及总生存期（OS）的相关性，发现治疗前SCGF-β水平与治疗反应存在关联。当SCGF-β水平超过163,295 pg/mL临界值时，患者中位OS显著缩短至12.03个月，而低于该阈值的患者中位OS可达28.87个月。这些结果表明SCGF-β可作为HCC治疗临床结局的预测指标，提示需要开展前瞻性研究以进一步验证该结果，并阐明SCGF-β相关治疗抵抗的潜在机制。
肿瘤(癌症)患者之家